FIERCELY FOCUSED
ON SOLUTIONS
ECTRIMS 2025
Cree B, et al. Long-Term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from 6 Years of ULTIMATE I and II Open-Label Extension (ECTRIMS 9.24.25)
Hersh C, et al. Real world clinical experience from ENABLE, the first Phase 4 observational study for patients with relapsing multiple sclerosis initiating ublituximab (ECTRIMS 9.24.25)
Singer B, et al. Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study (ECTRIMS 9.24.25)
CMSC 2025
Cree B, et al. No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long term ublituximab (UBL) treatment in patients with Relapsing Multiple Sclerosis (RMS) (CMSC 5.29.25)
Fox E, et al. Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) (CMSC 5.29.25)
Foley J, et al. Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study (CMSC 5.29.25)
AAN 2025
Cree B, et al. Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the Open- Label Extension of ULTIMATE I and II Studies (AAN 4.9.25)
Foley J, et al. Safety and Tolerability of a Modified Dosing Regimen of Ublituximab: Updates from the ENHANCE Study (AAN 4.9.25)
Fox E, et al. Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) (AAN 4.7.25)
Fox, E, et al. ENABLE: the first phase 4 observational study for patients with relapsing MS treated with ublituximab in real world clinical settings (AAN 4.7.25)
Steinman L, et al. No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long-term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS) (AAN 4.7.25)
ACTRIMS 2025
Foley J, et al. Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study (ACTRIMS 2.27.25)
Monson N, et al. The Design of a Study to Evaluate Fc Biology and Genetic Diversity in Multiple Sclerosis (ACTRIMS 2.27.25)
OUR PUBLICATION LIBRARY
We welcome you to explore our comprehensive publications database. All publications are available to download. Please select one or more fields from the list below to help narrow your search.| Date | Title | Author | Drug | Conferences | File | hf:tax:month-year | hf:tax:conference | hf:tax:therapeutics | hf:tax:drug |
|---|---|---|---|---|---|---|---|---|---|
| 09/24/2025 | Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study | et al., Singer B | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2025 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 09/24/2025 | Real world clinical experience from ENABLE, the first Phase 4 observational study for patients with relapsing multiple sclerosis initiating ublituximab | et al., Hersh C | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2025 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 09/24/2025 | Long-Term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from 6 Years of ULTIMATE I and II Open-Label | Cree B, et al. | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2025 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 05/29/2025 | Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study | et al., Foley J | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2025 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 05/29/2025 | Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) | et al., Fox E | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2025 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 05/29/2025 | No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long term ublituximab (UBL) treatment in patients with Relapsing Multiple Sclerosis (RMS) | Cree B, et al. | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2025 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 04/09/2025 | Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the OpenLabel Extension of ULTIMATE I and II Studies | Cree B, et al. | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2025 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/09/2025 | Safety and Tolerability of a Modified Dosing Regimen of Ublituximab: Updates from the ENHANCE Study | et al., Foley J | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2025 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/07/2025 | No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long-term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS) | et al., Steinman L | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2025 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/07/2025 | ENABLE: the first phase 4 observational study for patients with relapsing MS treated with ublituximab in real world clinical settings | et al., Fox E | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2025 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/07/2025 | Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) | et al., Fox E | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2025 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/03/2025 | Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series | Berkovich R, et al. | ublituximab (TG-1101) | Frontiers in Neurology Journal | 2025 | frontiers-in-neurology-journal | autoimmune | ublituximab-tg-1101 | |
| 04/03/2025 | The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function | Cree B, et al. | ublituximab (TG-1101) | CNS Drugs | 2025 | cns-drugs | autoimmune | ublituximab-tg-1101 | |
| 02/27/2025 | Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study | et al., Foley J | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2025 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 02/27/2025 | The Design of a Study to Evaluate Fc Biology and Genetic Diversity in Multiple Sclerosis | et al., Monson N | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2025 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 10/23/2024 | Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis | Alvarez E, et al. | ublituximab (TG-1101) | Frontiers in Neurology Journal | 2024 | frontiers-in-neurology-journal | autoimmune | ublituximab-tg-1101 | |
| 09/18/2024 | Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies | et al., Foley J | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2024 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 09/18/2024 | Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the Open-Label Extension of ULTIMATE I and II Studies | Cree B, et al. | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2024 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 09/18/2024 | Efficacy and Tolerability of Ublituximab after Transitioning from a Different Disease-Modifying Therapy: Updates from the ENHANCE Study | et al., Foley J | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2024 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 05/30/2024 | BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI (ublituximab-xiiy) | Bove R, et al. | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2024 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 05/30/2024 | A Post-Marketing Study Evaluating the Presence and Concentration of BRIUMVI®(ublituximab-xiiy) in Breastmilk (PROVIDE) | Bove R, et al. | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2024 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 04/17/2024 | Early Initiation of Ublituximab Treatment is Associated with Improved Disability Outcomes Among Treatment-Naïve Participants in ULTIMATE I and II | et al., Robertson D | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2024 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/17/2024 | Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies | et al., Robertson D | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2024 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/14/2024 | MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide | et al., Krieger S | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2024 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 02/29/2024 | Evaluating the Maintenance of Efficacy and Tolerability of Transitioning from IV Anti-CD20 Therapy to Ublituximab: ENHANCE Study Interim Data | et al., Singer B | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2024 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 02/29/2024 | MS Relapse Redefined: Addressing the Radiological/Pseudoexacerbation Paradox with High Efficacy Therapy in the ULTIMATE I and II Trials | Alvarez E, et al. | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2024 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 10/12/2023 | Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies | et al., Foley J | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2023 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/11/2023 | Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data | et al., Foley J | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2023 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/11/2023 | Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies | Arnold D, et al. | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2023 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 06/01/2023 | Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II | Alvarez E, et al. | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2023 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 04/25/2023 | Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytolysis (ADCC) Relative to Other Anti-CD20 mAbs | et al., Foley J | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2023 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/24/2023 | Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies | et al., Steinman L | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2023 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/24/2023 | Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis | Alvarez E, et al. | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2023 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 02/23/2023 | Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis | Alvarez E, et al. | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2023 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 02/23/2023 | Early, Transient Shift in Hematologic Parameters Observed With Ublituximab in the ULTIMATE I and II Phase 3 Studies | et al., Qian P | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2023 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 12/11/2022 | First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with BCell Lymphoma | Chea C, et al. | TG-1801 | American Society of Hematology Annual Meeting (ASH) | 2022 | american-society-of-hematology-annual-meeting-ash | oncology | tg-1801 | |
| 10/26/2022 | Functional Systems Scores and Expanded Disability Status Scale Score Evaluations in the ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis | Cree B, et al. | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2022 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/26/2022 | Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis | et al., Wray Sibyl | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2022 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/26/2022 | Ublituximab Treatment Is Associated With a Significant Proportion of Participants Achieving NEDA-4 | Alvarez E, et al. | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2022 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/26/2022 | Disease Outcomes With Ublituximab in Treatment-Naive Participants: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis | et al., Steinman L | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2022 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/26/2022 | B-Cell Depletion and Return in Participant Subgroups of the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis | et al., Fox E | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2022 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 08/25/2022 | Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis | et al., Steinman L | ublituximab (TG-1101) | New England Journal of Medicine (NEJM) | 2022 | new-england-journal-of-medicine-nejm | autoimmune | ublituximab-tg-1101 | |
| 06/27/2022 | Improved Quality of Life With Ublituximab in the ULTIMATE I and II Studies in Relapsing Multiple Sclerosis | et al., Selmaj K | ublituximab (TG-1101) | 5th Congress of the European Academy of Neurology (EAN) | 2022 | 5th-congress-of-the-european-academy-of-neurology-ean | autoimmune | ublituximab-tg-1101 | |
| 06/27/2022 | Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis: Pooled Post Hoc Analyses of the ULTIMATE I and II Studies | Cree B, et al. | ublituximab (TG-1101) | 5th Congress of the European Academy of Neurology (EAN) | 2022 | 5th-congress-of-the-european-academy-of-neurology-ean | autoimmune | ublituximab-tg-1101 | |
| 06/26/2022 | Ublituximab Efficacy Outcomes in Relapsing Multiple Sclerosis Patient Subgroups in the ULTIMATE I and II Studies | et al., Hartung P | ublituximab (TG-1101) | 5th Congress of the European Academy of Neurology (EAN) | 2022 | 5th-congress-of-the-european-academy-of-neurology-ean | autoimmune | ublituximab-tg-1101 | |
| 06/02/2022 | Improved Cognitive Processing Speed With Ublituximab in Patients With Highly Active Relapsing Multiple Sclerosis | et al., Robertson D | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2022 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 06/02/2022 | Infusion-Related Reactions With Ublituximab in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis | et al., Fox E | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2022 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 06/02/2022 | Reduced Disease Progression With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis | Alvarez E, et al. | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2022 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 04/05/2022 | Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS) | et al., Steinman L | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2022 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/03/2022 | Disability Improvements with Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations from the Phase 3 ULTIMATE I and II Studies | Cree B, et al. | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2022 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/03/2022 | Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Alvarez E, et al. | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2022 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/03/2022 | Infusion-Related Reactions (IRRs) with Ublituximab in Patients with Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses from the Phase 3 ULTIMATE I and II Studies | et al., Fox E | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2022 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 02/24/2022 | Reduction in T1 Hypointense Lesions with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis | Cree B, et al. | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2022 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 02/24/2022 | Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients with Relapsing Multiple Sclerosis | et al., Fox E | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2022 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 02/24/2022 | Neutralizing Antibodies and Antidrug Antibodies in the Ublituximab Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis | Alvarez E, et al. | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2022 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 12/13/2021 | Favorable Outcomes for Patients with Co-morbidities or Concomitant Medications Treated with U2: A Retrospective Analysis of UNITY-CLL Phase 3 Trial | et al., Pinilla-Ibarz J | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2021 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/13/2021 | Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) by Treatment Status: A Sub-analysis of the Phase 3 UNITY-CLL Study | et al., Jacobs R | American Society of Hematology Annual Meeting (ASH) | 2021 | american-society-of-hematology-annual-meeting-ash | oncology | |||
| 12/12/2021 | A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): a Minimal Residual Disease (MRD)-driven, Time-limited Approach | et al., Roeker L | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2021 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/12/2021 | Efficacy and Safety of Umbralisib and Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Burke J, et al. | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2021 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/11/2021 | The Combination of Umbralisib Plus Ublituximab is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global UNITY-NHL Trial | Chavez J, et al. | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2021 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/11/2021 | The Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor TG-1701 as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies | Cheah C, et al. | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2021 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 10/14/2021 | Ublituximab Is Associated With Significant Improvement in the Multiple Sclerosis Functional Composite (MSFC): Results From the Phase 3 ULTIMATE I & II Studies | et al., Steinman L | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2021 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/14/2021 | Phase 3 Results of the ULTIMATE I & II Global Studies: Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis | et al., Steinman L | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2021 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 09/21/2021 | Integrated Safety Analysis of Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor, in Relapsed/Refractory Lymphoid Malignancies | Davids M, et al. | umbralisib (TGR-1202) | Blood Advances Journal – published by The American Society of Hematology | 2021 | blood-advances-journal-published-by-the-american-society-of-hematology | oncology | umbralisib-tgr-1202 | |
| 09/19/2021 | A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Barr, P et al. | TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2021 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | tg-1701 ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 09/19/2021 | TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia | Cheah C, et al. | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2021 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | |||
| 09/18/2021 | Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up | et al., Roeker L | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2021 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 09/18/2021 | Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study | et al., Jurczak W | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2021 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 09/18/2021 | Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up | et al., Roeker L | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | ||
| 06/18/2021 | Antitumoral Activity of the Novel BTK Inhibitor TG-1701 is Associated with Disruption of Ikaros Signaling and Improvement of Anti-CD20 Therapy in B-cell Non-Hodgkin Lymphoma | et al., Roue G | TG-1701 | International Congress on Malignant Lymphoma (ICML) | 2021 | international-congress-on-malignant-lymphoma-icml | oncology | tg-1701 | |
| 06/18/2021 | Updated Results of the Selective Bruton Tyrosine kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies | Cheah C, et al. | TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | International Congress on Malignant Lymphoma (ICML) | 2021 | international-congress-on-malignant-lymphoma-icml | oncology | tg-1701 ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 06/18/2021 | Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 ULTIMATE I and II Trials | et al., Steinman L | ublituximab (TG-1101) | 5th Congress of the European Academy of Neurology (EAN) | 2021 | 5th-congress-of-the-european-academy-of-neurology-ean | autoimmune | ublituximab-tg-1101 | |
| 06/11/2021 | Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies | Cheah C, et al. | Congress of the European Hematology Association (EHA) | 2021 | congress-of-the-european-hematology-association-eha | oncology | |||
| 06/04/2021 | Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib(U2) in Patients (pts) with B-cell Malignancies | Cheah C, et al. | TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2021 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | tg-1701 ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 06/04/2021 | VIDEO: Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies | Cheah C, et al. | TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2021 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | tg-1701 ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 04/17/2021 | Efficacy and Safety of Ublituximab vs Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results from Two Phase 3 Studies ULTIMATE I & ULTIMATE II American Academy of Neurology | et al., Steinman L | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2021 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 03/09/2021 | Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients with Relapsed/Refractory Indolent Lymphoma | et al., Fowler N | umbralisib (TGR-1202) | Journal of Clinical Oncology | 2021 | journal-of-clinical-oncology | oncology | umbralisib-tgr-1202 | |
| 02/22/2021 | A Phase 3, Randomized Trial of Ublituximab Plus Ibrutinib for Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukaemia | et al., Sharman J | ublituximab (TG-1101) | THE LANCET Haematology | 2021 | the-lancet-haematology | ublituximab-tg-1101 | ||
| 12/07/2020 | A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Barr P, et al. | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/07/2020 | Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial | et al., Zinzani P | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/07/2020 | Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL | et al., Gribben J | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/07/2020 | VIDEO: Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL | Gribben, J et al. | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/07/2020 | VIDEO: Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial | P et al., Zinzani | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/07/2020 | VIDEO: A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Barr, P et al. | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/05/2020 | Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies | Cheah C, et al. | TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | tg-1701 ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/05/2020 | VIDEO: Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies | Cheah C, et al. | TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | tg-1701 ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 12/02/2020 | Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy | et al., Mato A | umbralisib (TGR-1202) | Blood Medical Journal – published by the American Society of Hematology (Blood) | 2020 | blood-medical-journal-published-by-the-american-society-of-hematology-blood | oncology | umbralisib-tgr-1202 | |
| 11/04/2020 | Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study | et al., Gribben J | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 11/04/2020 | Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global UNITY-NHL Trial | et al., Zinzani P | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 11/04/2020 | A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Barr P, et al. | ublituximab (TG-1101), umbralisib (TGR-1202), umbralisib + ublituximab (U2) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 umbralisib-ublituximab-u2 | |
| 11/04/2020 | Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies | Cheah C, et al. | TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2020 | american-society-of-hematology-annual-meeting-ash | oncology | tg-1701 ublituximab-tg-1101 umbralisib-tgr-1202 | |
| 07/08/2020 | The Dual PI3Kδ/CK1ε Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects on CLL T Cells | Pinilla-Ibarz J. et al. | umbralisib (TGR-1202) | Blood Advances Journal – published by The American Society of Hematology | 2020 | blood-advances-journal-published-by-the-american-society-of-hematology | oncology | umbralisib-tgr-1202 | |
| 06/22/2020 | TG-1701, a Novel Irreversible Bruton’s Kinase (BTK) Inhibitor, Cooperates with Ublituximab-Driven ADCC and ADCP in In Vitro and In Vivo Models of Ibrutinib-Resistant Mantle Cell Lymphoma | et al., Ribeiro M | TG-1701 | American Association for Cancer Research Annual Meeting (AACR) | 2020 | american-association-for-cancer-research-annual-meeting-aacr | oncology | tg-1701 | |
| 06/12/2020 | Long term Results of a Phase I/ Ib Study of Ibrutinib in Combination with Umbralisib in Patients with Relapsed/Refractory CLL or MCL | Davids M, et al. | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2020 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/12/2020 | Safety and Activity of the Once Daily Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma | Cheah C, et al. | TG-1701 | Congress of the European Hematology Association (EHA) | 2020 | congress-of-the-european-hematology-association-eha | oncology | tg-1701 | |
| 05/29/2020 | Effect of Adding Ublituximab to Ibrutinib on PFS, ORR, and MRD Negativity in Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results of the GENUINE Phase III Study | et al., Sharman J | ublituximab (TG-1101) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2020 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | ublituximab-tg-1101 | |
| 04/30/2020 | A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis | et al., Fox E | ublituximab (TG-1101) | Multiple Sclerosis Journal | 2020 | multiple-sclerosis-journal | autoimmune | ublituximab-tg-1101 | |
| 02/27/2020 | Long-term Follow-up Results From the Phase 2 Multicenter Study of Ublituximab(UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients With Relapsing Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2020 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 12/09/2019 | Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies | Cheah C, et al. | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2019 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/08/2019 | A Phase 1/2 Study of Umbralisib, Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). | Barr P, et al. | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2019 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 11/21/2019 | Ublituximab and Umbralisib in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | et al., Lunning M | umbralisib (TGR-1202) | Blood Medical Journal – published by the American Society of Hematology (Blood) | 2019 | blood-medical-journal-published-by-the-american-society-of-hematology-blood | oncology | umbralisib-tgr-1202 | |
| 09/23/2019 | A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy | et al., Mato A | umbralisib (TGR-1202) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2019 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | umbralisib-tgr-1202 | |
| 09/23/2019 | Phase I/II Triple Therapy Study of Umbralisib and Ublituximab (U2) Combined with Checkpoint Inhibition in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter’s Transformation (RT) | et al., Mato A | umbralisib (TGR-1202) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2019 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | umbralisib-tgr-1202 | |
| 09/12/2019 | Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2019 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 09/12/2019 | Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) | Cree B, et al. | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2019 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 07/12/2019 | Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | 5th Congress of the European Academy of Neurology (EAN) | 2019 | 5th-congress-of-the-european-academy-of-neurology-ean | autoimmune | ublituximab-tg-1101 | |
| 06/20/2019 | Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation | et al., Mato A | ublituximab (TG-1101), umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2019 | international-congress-on-malignant-lymphoma-icml | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 | |
| 06/20/2019 | A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy | et al., Mato A | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2019 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 06/19/2019 | Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study | et al., Zinzani P | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2019 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 06/14/2019 | The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL | et al., Ribeiro M | TG-1801 | Congress of the European Hematology Association (EHA) | 2019 | congress-of-the-european-hematology-association-eha | oncology | tg-1801 | |
| 06/09/2019 | The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL | et al., Ribeiro M | TG-1801, ublituximab (TG-1101), umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2019 | international-congress-on-malignant-lymphoma-icml | oncology | tg-1801 ublituximab-tg-1101 umbralisib-tgr-1202 | |
| 06/04/2019 | Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-label, Registration Directed Phase 2 Study | et al., Fowler N | umbralisib (TGR-1202) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2019 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | umbralisib-tgr-1202 | |
| 05/07/2019 | Open Label Extension (OLE) of a Phase 2 Multicenter Study Of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2019 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 05/03/2019 | B cell Depletion with Ublituximab Reshapes the T Cell Profile in Multiple Sclerosis Patients | et al., Lovett-Racke A | ublituximab (TG-1101) | Journal of Neuroimmunology | 2019 | journal-of-neuroimmunology | autoimmune | ublituximab-tg-1101 | |
| 04/01/2019 | TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting | et al., Fowler N | umbralisib (TGR-1202) | American Association for Cancer Research Annual Meeting (AACR) | 2019 | american-association-for-cancer-research-annual-meeting-aacr | oncology | umbralisib-tgr-1202 | |
| 02/28/2019 | Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2019 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 02/01/2019 | Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma: A Phase 1 Dose Escalation and Expansion Trial | et al., Nastoupil L | umbralisib (TGR-1202) | New England Journal of Medicine (NEJM) | 2019 | new-england-journal-of-medicine-nejm | oncology | umbralisib-tgr-1202 | |
| 12/14/2018 | Umbralisib in Combination with Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia or Mantle Cell Lymphoma: A Multicentre Phase 1–1b Study | Davids M, et al. | umbralisib (TGR-1202) | THE LANCET Haematology | 2018 | the-lancet-haematology | oncology | umbralisib-tgr-1202 | |
| 12/03/2018 | Combination of Umbralisib, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma | et al., Lunning M | ublituximab (TG-1101), umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2018 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 | |
| 12/02/2018 | Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation | et al., Mato A | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2018 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 10/11/2018 | Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2018 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 06/18/2018 | Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered AntiCD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | Congress of the European Academy of Neurology (EAN) | 2018 | congress-of-the-european-academy-of-neurology-ean | autoimmune | ublituximab-tg-1101 | |
| 06/16/2018 | Resurrecting response to ruxolitinib: A Phase I study of ruxolitinib and umbralisib (TGR-1202) in ruxolitinib-experienced myelofibrosis | Moyo et al. | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2018 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/16/2018 | A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy | et al., Mato A | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2018 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/15/2018 | Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid Malignancies | Davids M, et al. | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2018 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/15/2018 | TG-1701 is a novel, orally available and covalently bound BTK inhibitor | E et al., Normant | TG-1701 | Congress of the European Hematology Association (EHA) | 2018 | congress-of-the-european-hematology-association-eha | oncology | tg-1701 | |
| 06/04/2018 | A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy | et al., Mato A | umbralisib (TGR-1202) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2018 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | umbralisib-tgr-1202 | |
| 04/24/2018 | Final MRI Results at 6 Months from a Phase 2 Multicenter Study of Ublituximab, A Novel Glyocoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions | et al., Inglese M | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2018 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/18/2018 | TG-1601 is a Novel BET Inhibitor with Strong Binding Affinity and Long-lasting Effect in Pre-clinical Models | E et al., Normant | TG-1601 | American Association for Cancer Research Annual Meeting (AACR) | 2018 | american-association-for-cancer-research-annual-meeting-aacr | oncology | tg-1601 | |
| 02/20/2018 | Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study | Burris H, et al. | umbralisib (TGR-1202) | THE LANCET Oncology | 2018 | the-lancet-oncology | oncology | umbralisib-tgr-1202 | |
| 02/01/2018 | 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis | et al., Fox E | ublituximab (TG-1101) | Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2018 | americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims | autoimmune | ublituximab-tg-1101 | |
| 12/11/2017 | KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy | et al., Mato A | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2017 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/11/2017 | An Integrated Safety Analysis of the Next Generation PI3K Delta Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies | Davids M, et al. | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2017 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/11/2017 | PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation | D et al, Friedman | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2017 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/10/2017 | Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL | et al., Mato A | ublituximab (TG-1101), umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2017 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 | |
| 12/10/2017 | Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas | et al., O'Connor | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2017 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/10/2017 | Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model | et al., Maharaj | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2017 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 10/27/2017 | Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets | et al., Fox E, Lovett-Racke A | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2017 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/26/2017 | Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis | et al., Fox E | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2017 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 10/26/2017 | Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease | et al., Inglese M | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2017 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 06/24/2017 | Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL | et al., Nastoupil L | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2017 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/24/2017 | Combination of TGR-1202, Ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma | et al., Lunning M | ublituximab (TG-1101) | Congress of the European Hematology Association (EHA) | 2017 | congress-of-the-european-hematology-association-eha | oncology | ublituximab-tg-1101 | |
| 06/24/2017 | Rapid and Robust B Cell Depletion in Preliminary Results of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing forms of Multiple Sclerosis (RMS) | et al., Fox E | ublituximab (TG-1101) | Congress of the European Academy of Neurology (EAN) | 2017 | congress-of-the-european-academy-of-neurology-ean | autoimmune | ublituximab-tg-1101 | |
| 06/16/2017 | Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study | et al., Mato A | ublituximab (TG-1101) | International Congress on Malignant Lymphoma (ICML) | 2017 | international-congress-on-malignant-lymphoma-icml | oncology | ublituximab-tg-1101 | |
| 06/16/2017 | Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL | et al., Nastoupil L | ublituximab (TG-1101), umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2017 | international-congress-on-malignant-lymphoma-icml | oncology | ublituximab-tg-1101 umbralisib-tgr-1202 | |
| 06/15/2017 | Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma | et al., Lunning M | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2017 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 06/14/2017 | Updated Results of a Multicenter Phase I/IB Study of Umbralisib (TGR-1202) in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL | Davids M, et al. | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2017 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 06/05/2017 | Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL | et al., Nastoupil L | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2017 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/03/2017 | Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study | et al., Sharman J | ublituximab (TG-1101) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2017 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | ublituximab-tg-1101 | |
| 05/26/2017 | Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, RMS Patients | et al., Fox E, Lovett-Racke A | ublituximab (TG-1101) | Annual Meeting of Consortium of MS Centers (CMSC) | 2017 | annual-meeting-of-consortium-of-ms-centers-cmsc | autoimmune | ublituximab-tg-1101 | |
| 05/15/2017 | TGR-1202– A novel PI3K-delta inhibitor that differentially regulates T cells in CLL | et al., Pinilla-Ibarz | umbralisib (TGR-1202) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2017 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | umbralisib-tgr-1202 | |
| 05/15/2017 | TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL: Updated Results of a Multicenter Phase I/Ib Study | Davids M, et al. | umbralisib (TGR-1202) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2017 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | umbralisib-tgr-1202 | |
| 04/28/2017 | Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion | et al., Fox E, Lovett-Racke A | ublituximab (TG-1101) | American Academy of Neurology Annual Meeting (AAN) | 2017 | american-academy-of-neurology-annual-meeting-aan | autoimmune | ublituximab-tg-1101 | |
| 04/04/2017 | Preclinical Characterization of a Fully Human lgG1 Anti PD-L1 mab CK-301 | et al., Gorelik L, Marasco W | Anti PD-L1 | American Association for Cancer Research Annual Meeting (AACR) | 2017 | american-association-for-cancer-research-annual-meeting-aacr | oncology | anti-pd-l1 | |
| 03/05/2017 | KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy | Dorsey, et al., Mato | umbralisib (TGR-1202) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2017 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | umbralisib-tgr-1202 | |
| 02/21/2017 | Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial | Burke et al., Sharman | ublituximab (TG-1101) | British Journal of Haematology (BJH) | 2017 | british-journal-of-haematology-bjh | oncology | ublituximab-tg-1101 | |
| 12/16/2016 | A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab | et al., O'Connor, Sawas | ublituximab (TG-1101) | British Journal of Haematology (BJH) | 2016 | british-journal-of-haematology-bjh | oncology | ublituximab-tg-1101 | |
| 12/05/2016 | TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. | Davids M, et al. | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2016 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/05/2016 | Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3K Delta Inhibitor TGR-1202 in Myelofibrosis. | Moyo et al. | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2016 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/05/2016 | Combination of Ublituximab, TGR-1202 and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma. | et al., Lunning M | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2016 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/05/2016 | A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma | Ramchandran et al. | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2016 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/04/2016 | Silencing cMyc Translation as a Therapeutic Strategy Through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. | Deng C, et al. | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2016 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/04/2016 | Modulation of T cell Compartment in a Preclinical CLL Murine Model by a Selective PI3K delta inhibitor, TGR-1202. | et al., Maharaj | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2016 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 10/27/2016 | Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies | Deng C, et al., O'Connor O | umbralisib (TGR-1202) | Blood Medical Journal – published by the American Society of Hematology (Blood) | 2016 | blood-medical-journal-published-by-the-american-society-of-hematology-blood | oncology | umbralisib-tgr-1202 | |
| 09/14/2016 | Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica Relapses | et al., Levy M, Mealy M | ublituximab (TG-1101) | European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 2016 | european-committee-for-treatment-and-research-in-multiple-sclerosis-ectrims | autoimmune | ublituximab-tg-1101 | |
| 06/03/2016 | Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. | Burris H, et al., Flinn I | umbralisib (TGR-1202) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2016 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | umbralisib-tgr-1202 | |
| 06/01/2016 | Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL. | Davids M, et al. | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2016 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/01/2016 | Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. | et al., Mato A | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2016 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/01/2016 | Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated Analysis of TGR-1202 monotherapy and combined with ublituximab | et al., O'Connor O | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2016 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 04/16/2016 | Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor. | et al., Pinilla-Ibarz | umbralisib (TGR-1202) | American Association for Cancer Research Annual Meeting (AACR) | 2016 | american-association-for-cancer-research-annual-meeting-aacr | oncology | umbralisib-tgr-1202 | |
| 12/08/2015 | Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. | et al., Sharman J | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2015 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/08/2015 | Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas. | Deng C, et al. | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2015 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/08/2015 | Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K- Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. | et al., O'Connor O | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2015 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/08/2015 | A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia. | et al., Mahadevan D | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | ||
| 12/08/2015 | A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia. | et al., Mahadevan D | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2015 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 11/08/2015 | Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. | et al., Sharman J | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2015 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 09/09/2015 | a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL. | et al., O'Brien | ublituximab (TG-1101) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | ublituximab-tg-1101 | ||
| 09/09/2015 | a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL. | et al., O'Brien | ublituximab (TG-1101) | International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | 2015 | international-workshop-on-chronic-lymphocytic-leukemia-iwcll | oncology | ublituximab-tg-1101 | |
| 06/20/2015 | Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. | et al., Lunning M | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2015 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 06/20/2015 | Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL. | Burke J, et al. | ublituximab (TG-1101) | International Congress on Malignant Lymphoma (ICML) | 2015 | international-congress-on-malignant-lymphoma-icml | oncology | ublituximab-tg-1101 | |
| 06/20/2015 | Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies. | et al., Nastoupil L | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2015 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 06/20/2015 | Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma. | et al., O'Connor | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2015 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 06/14/2015 | Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. | et al., Lunning M | ublituximab (TG-1101) | Congress of the European Hematology Association (EHA) | 2015 | congress-of-the-european-hematology-association-eha | oncology | ublituximab-tg-1101 | |
| 06/14/2015 | Clinical Activity and Safety Profile of TGR-1202 a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with CLL and B-Cell Lymphoma. | et al., O'Connor | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2015 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/02/2015 | Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. | et al., Lunning M, O'Brien S | umbralisib (TGR-1202) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2015 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | umbralisib-tgr-1202 | |
| 06/02/2015 | Safety and Activity of the Chemotherapy-free Triplet of Ublituximab, TGR-1202 and ibrutinib in Relapsed B-cell Malignancies. | et al., Fowler N, O'Brien S | ublituximab (TG-1101) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2015 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | ublituximab-tg-1101 | |
| 06/02/2015 | Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily Pi3k Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. | Burris H, et al., Flinn I | umbralisib (TGR-1202) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2015 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | umbralisib-tgr-1202 | |
| 04/18/2015 | IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas. | et al., Marschke K, Vajda E | IRAK4 | American Association for Cancer Research Annual Meeting (AACR) | 2015 | american-association-for-cancer-research-annual-meeting-aacr | oncology | irak4 | |
| 03/08/2015 | Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. | et al., Lunning M | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2015 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/09/2014 | Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. | et al., Lunning M, O'Brien S | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2014 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/09/2014 | Ublituximab (TG-1101) a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL: Results of a Phase II Trial. | et al., Greenwald D, Sharman J | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2014 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/09/2014 | The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts. | et al., Locatelli | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2014 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/09/2014 | TGR-1202, a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. | Burris H, et al., Flinn I | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2014 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/09/2014 | Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma. | Deng C, et al., O'Connor O | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2014 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 07/21/2014 | A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma. | et al., Lunning M, O'Brien S | ublituximab (TG-1101) | Pan Pacific Lymphoma Conference (PPLC) | 2014 | pan-pacific-lymphoma-conference-pplc | oncology | ublituximab-tg-1101 | |
| 06/13/2014 | Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial. | et al., O'Connor O, Sharman J | ublituximab (TG-1101) | Congress of the European Hematology Association (EHA) | 2014 | congress-of-the-european-hematology-association-eha | oncology | ublituximab-tg-1101 | |
| 06/13/2014 | Ublituximab (TG-1101), A Novel Anti-CD20 Monoclonal Antibody for Rituximab Relapsed/Refractory B-Cell Malignancies. | et al., Farber C, O'Connor O | ublituximab (TG-1101) | Congress of the European Hematology Association (EHA) | 2014 | congress-of-the-european-hematology-association-eha | oncology | ublituximab-tg-1101 | |
| 06/13/2014 | Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. | Burris H, et al., Flinn I | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2014 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 05/30/2014 | Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. | Burris H, et al., Flinn I | umbralisib (TGR-1202) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2014 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | umbralisib-tgr-1202 | |
| 05/30/2014 | A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab. | Changchun D, et al., O'Connor O | ublituximab (TG-1101) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2014 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | ublituximab-tg-1101 | |
| 04/09/2014 | The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro. | et al., Friedman D, Lanasa M | umbralisib (TGR-1202) | American Association for Cancer Research Annual Meeting (AACR) | 2014 | american-association-for-cancer-research-annual-meeting-aacr | oncology | umbralisib-tgr-1202 | |
| 04/09/2014 | The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. | Carlo-Stella C, et al., Locatelli S | umbralisib (TGR-1202) | American Association for Cancer Research Annual Meeting (AACR) | 2014 | american-association-for-cancer-research-annual-meeting-aacr | oncology | umbralisib-tgr-1202 | |
| 12/10/2013 | The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. | Carlo-Stella C, et al., Locatelli S | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2013 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/10/2013 | The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells. | Deng C, et al., O'Connor O | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2013 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/10/2013 | A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies. | et al., Patel M, Savona M | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2013 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 09/09/2013 | The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro. | et al., Friedman D, Lanasa M | umbralisib (TGR-1202) | American Association for Cancer Research Annual Meeting (AACR) | 2013 | american-association-for-cancer-research-annual-meeting-aacr | oncology | umbralisib-tgr-1202 | |
| 06/14/2013 | Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies. | Changchun D, et al., O'Connor O | ublituximab (TG-1101) | Congress of the European Hematology Association (EHA) | 2013 | congress-of-the-european-hematology-association-eha | oncology | ublituximab-tg-1101 | |
| 06/14/2013 | A Novel, PI3K-Delta Specific Inhibitor in Multiple Myeloma. | et al., Vakkalanka S, Viswanadha S | umbralisib (TGR-1202) | Congress of the European Hematology Association (EHA) | 2013 | congress-of-the-european-hematology-association-eha | oncology | umbralisib-tgr-1202 | |
| 06/04/2013 | Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). | Cazin B, et al., Ribrag V | ublituximab (TG-1101) | Congress of the European Hematology Association (EHA) | 2013 | congress-of-the-european-hematology-association-eha | oncology | ublituximab-tg-1101 | |
| 06/02/2013 | A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients. | Changchun D, et al., O'Connor O | ublituximab (TG-1101) | American Society of Clinical Oncology Annual Meeting (ASCO) | 2013 | american-society-of-clinical-oncology-annual-meeting-asco | oncology | ublituximab-tg-1101 | |
| 06/01/2013 | Novel PI3K Inhibitors Demonstrate Marked Cytotoxicity in Models of T-Cell Lymphoma, Caused Apoptosis and Were Synergistic with the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Models of B-Cell Lymphoma | Changchun, Deng | umbralisib (TGR-1202) | International Congress on Malignant Lymphoma (ICML) | 2013 | international-congress-on-malignant-lymphoma-icml | oncology | umbralisib-tgr-1202 | |
| 03/10/2013 | Combined Carfilzomib and Selective PI3K-d Inhibition (TGR-1202) Results in Enhanced Myeloma Cell Apoptosis. | et al., Lonial S, Torre C | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2013 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/11/2012 | Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom’s Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab. | et al., Le Garff-Tavernier M, Leblond V | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2012 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/11/2012 | Ublituximab (TGTX-1101), a Novel, Third-Generation Anti-CD20 Antibody Demonstrates Enhanced Antitumor Activity Compared to Rituximab in Primary CNS and Intraocular Lymphoma Murine Models. | Donnou S, et al., Fisson S | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2012 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/11/2012 | Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-clinical In Vitro and In Vivo Models. | Barth M, Czuczman M, et al. | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2012 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/11/2012 | TGR-1202 Suppresses AML and ALL Cells Via Selective Inhibition of PI3K-delta Kinase. | et al., Savona M, Vakkalanka S | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2012 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/11/2012 | Novel PI3K Inhibitors Demonstrate Marked Cytotoxicity in Models of T-Cell Lymphoma, Caused Apoptosis and Were Synergistic with the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Models of B-Cell Lymphoma | Changchun D, et al., O'Connor O | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2012 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 12/11/2012 | Comparison of the PI3K-delta Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro. | et al., Friedman D, Lanasa M, Weinberg B | umbralisib (TGR-1202) | American Society of Hematology Annual Meeting (ASH) | 2012 | american-society-of-hematology-annual-meeting-ash | oncology | umbralisib-tgr-1202 | |
| 04/04/2012 | Inhibition of PI3Kd kinase by a selective small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth. | et al., Vakkalanka S, Viswanadha S | umbralisib (TGR-1202) | American Association for Cancer Research Annual Meeting (AACR) | 2012 | american-association-for-cancer-research-annual-meeting-aacr | oncology | umbralisib-tgr-1202 | |
| 12/13/2011 | TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20. | Echelard Y, et al., Meade HM | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2011 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/13/2011 | Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). | Cartron G, Cazin B, Coiffier B, et al. | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2011 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/13/2011 | LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody, Displays Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models. | et al., Fournès B, Tourais Esteves I | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2011 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/13/2011 | Comparison of Cell Lysis Mediated by LFB-R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of CD20. | Bellon A, et al., Salcedo M | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2011 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 | |
| 12/07/2010 | A Phase I study of LFB-R603, a Novel Anti-CD20 Antibody, in Patients with Relapsed Chronic Lymphocytic Leukemia. | Cartron G, Cazin B, et al. | ublituximab (TG-1101) | American Society of Hematology Annual Meeting (ASH) | 2010 | american-society-of-hematology-annual-meeting-ash | oncology | ublituximab-tg-1101 |
